Ceftriaxone to PRevent pneumOnia and inflammaTion aftEr Cardiac arresT (PROTECT): study protocol for a randomized, placebo-controlled trial

Pneumonia is the most common infection after out-of-hospital cardiac arrest (OHCA) occurring in up to 65% of patients who remain comatose after return of spontaneous circulation. Preventing infection after OHCA may (1) reduce exposure to broad-spectrum antibiotics, (2) prevent hemodynamic derangemen...

Full description

Saved in:
Bibliographic Details
Published in:Current controlled trials in cardiovascular medicine 2022-03, Vol.23 (1), p.197-13, Article 197
Main Authors: Gagnon, David J, Ryzhov, Sergey V, May, Meghan A, Riker, Richard R, Geller, Bram, May, Teresa L, Bockian, Sarah, deKay, Joanne T, Eldridge, Ashley, Van der Kloot, Thomas, Lerwick, Patricia, Lord, Christine, Lucas, F Lee, Mailloux, Patrick, McCrum, Barbara, Searight, Meghan, Wirth, Joel, Zuckerman, Jonathan, Sawyer, Douglas, Seder, David B
Format: Article
Language:English
Subjects:
Antibiotics
Bacteria
Bacterial infections
Bacterial pneumonia
Cardiac arrest
Cardiology
Ceftriaxone
Ceftriaxone - adverse effects
Ceftriaxone sodium
Complications and side effects
Corporate sponsorship
Critical care
Dosage and administration
Double-Blind Method
Emergency medical care
Hospitals
Humans
Hypothermia
Inflammation
Informed consent
Medicine
Mortality
Neurosciences
Ostomy
Out-of-Hospital Cardiac Arrest - diagnosis
Out-of-Hospital Cardiac Arrest - drug therapy
Patients
Pneumonia
Prevention
Randomized Controlled Trials as Topic
Research centers
Risk factors
Staphylococcus infections
Streptococcus infections
Study Protocol
Targeted temperature management
Testing
Treatment Outcome
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Pneumonia is the most common infection after out-of-hospital cardiac arrest (OHCA) occurring in up to 65% of patients who remain comatose after return of spontaneous circulation. Preventing infection after OHCA may (1) reduce exposure to broad-spectrum antibiotics, (2) prevent hemodynamic derangements due to local and systemic inflammation, and (3) prevent infection-associated morbidity and mortality. The ceftriaxone to PRevent pneumOnia and inflammaTion aftEr Cardiac arrest (PROTECT) trial is a randomized, placebo-controlled, single-center, quadruple-blind (patient, treatment team, research team, outcome assessors), non-commercial, superiority trial to be conducted at Maine Medical Center in Portland, Maine, USA. Ceftriaxone 2 g intravenously every 12 h for 3 days will be compared with matching placebo. The primary efficacy outcome is incidence of early-onset pneumonia occurring
ISSN:1745-6215
1745-6215
DOI:10.1186/s13063-022-06127-w